MENU
+Compare
GRFS
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$7.27
Change
+$0.03 (+0.41%)
Capitalization
5.48B

GRFS Grifols SA Forecast, Technical & Fundamental Analysis

a manufacturer of plasma-derived biological medicines

GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for GRFS with price predictions
Jan 14, 2025

GRFS sees MACD Histogram crosses below signal line

GRFS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 14, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GRFS as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

GRFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.716) is normal, around the industry mean (5.632). P/E Ratio (68.679) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.266) is also within normal values, averaging (3.004). Dividend Yield (0.045) settles around the average of (0.164) among similar stocks. GRFS's P/S Ratio (0.637) is slightly lower than the industry average of (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

View a ticker or compare two or three
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

GRFS is expected to report earnings to rise 18.26% to 20 cents per share on February 27

Grifols SA GRFS Stock Earnings Reports
Q4'24
Est.
$0.20
Q3'24
Missed
by $0.04
Q2'24
Est.
$0.09
Q1'24
Missed
by $0.07
Q4'23
Est.
$0.23
The last earnings report on November 07 showed earnings per share of 17 cents, missing the estimate of 21 cents. With 531.26K shares outstanding, the current market capitalization sits at 5.48B.
A.I.Advisor
published Dividends

GRFS paid dividends on June 14, 2021

Grifols SA GRFS Stock Dividends
А dividend of $0.46 per share was paid with a record date of June 14, 2021, and an ex-dividend date of June 03, 2021. Read more...
A.I. Advisor
published General Information

General Information

a manufacturer of plasma-derived biological medicines

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Avinguda de la Generalitat, 152
Phone
+34 935712200
Employees
23744
Web
https://www.grifols.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

GRFS and Stocks

Correlation & Price change

A.I.dvisor tells us that GRFS and GIFOF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and GIFOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.41%
GIFOF - GRFS
26%
Poorly correlated
N/A
BIIB - GRFS
20%
Poorly correlated
-0.48%
AMRN - GRFS
20%
Poorly correlated
+0.72%
ALPMY - GRFS
11%
Poorly correlated
-0.93%
SCLX - GRFS
9%
Poorly correlated
-4.31%
More